Literature DB >> 24653790

Complementary and alternative medications in hepatitis C infection.

Dina L Halegoua-De Marzio1, Jonathan M Fenkel1.   

Abstract

Chronic hepatitis C (CHC) infection affects almost 3% of the global population and can lead to cirrhosis, liver failure, and hepatocellular carcinoma in a significant number of those infected. Until recently, the only treatments available were pegylated interferon and ribavirin, which traditionally were not very effective and have considerable side effects. For this reason, interest in complementary and alternative medications (CAM) in the management of hepatitis C has been investigated. Some CAM has demonstrated therapeutic potential in chronic hepatitis C treatment. Unfortunately, some CAM has been shown to have the potential to cause drug-induced liver injury. This article will review and evaluate many of the natural molecules that interact with the hepatitis C virus (HCV) life cycle and discuss their potential use and safety in HCV therapy, as well as highlight some important interactions between medical and complementary treatments.

Entities:  

Keywords:  Direct acting antivirals; Hepatitis C infection; Hepatotoxicity; Herbal treatments; Natural molecules

Year:  2014        PMID: 24653790      PMCID: PMC3953807          DOI: 10.4254/wjh.v6.i1.9

Source DB:  PubMed          Journal:  World J Hepatol


  91 in total

1.  Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP.

Authors:  L J Wilcox; N M Borradaile; L E de Dreu; M W Huff
Journal:  J Lipid Res       Date:  2001-05       Impact factor: 5.922

2.  The determination of glycyrrhizin in selected UK liquorice products.

Authors:  E A Spinks; G R Fenwick
Journal:  Food Addit Contam       Date:  1990 Nov-Dec

3.  Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.

Authors:  Saif Abu-Mouch; Zvi Fireman; Jacob Jarchovsky; Abdel-Rauf Zeina; Nimer Assy
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

4.  Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine.

Authors:  Haitao Luo; Lili Tang; Meng Tang; Madhavi Billam; Tianren Huang; Jiahua Yu; Zhongliang Wei; Yongqiang Liang; Kaibo Wang; Zhen-Quan Zhang; Lisheng Zhang; Jia-Sheng Wang
Journal:  Carcinogenesis       Date:  2005-06-01       Impact factor: 4.944

Review 5.  Vitamin D in liver diseases: from mechanisms to clinical trials.

Authors:  Yuan-Ping Han; Ming Kong; Sujun Zheng; Yan Ren; Longdon Zhu; Hongbo Shi; Zhongping Duan
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

6.  Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.

Authors:  Meital Gal-Tanamy; Larisa Bachmetov; Amiram Ravid; Ruth Koren; Arie Erman; Ran Tur-Kaspa; Romy Zemel
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 7.  Effects of tea consumption on nutrition and health.

Authors:  C S Yang; J M Landau
Journal:  J Nutr       Date:  2000-10       Impact factor: 4.798

8.  The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.

Authors:  Edward J Gane; Frank Weilert; David W Orr; Geraldine F Keogh; Michael Gibson; Michelle M Lockhart; Christopher M Frampton; Kenneth M Taylor; Robin A J Smith; Michael P Murphy
Journal:  Liver Int       Date:  2010-05-18       Impact factor: 5.828

9.  Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors:  Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

10.  Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin.

Authors:  Yaakov Nahmias; Jonathan Goldwasser; Monica Casali; Daan van Poll; Takaji Wakita; Raymond T Chung; Martin L Yarmush
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

View more
  2 in total

Review 1.  Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends.

Authors:  Sailaja Kesiraju; Praneeth Srikanti; S Sahariah
Journal:  Virusdisease       Date:  2017-08-24

2.  Complementary and Alternative Medicines for the Treatment of Hepatitis C: Perspectives of Users and CAM Practitioners.

Authors:  Salamat Ali; Shahan Ullah; Vibhu Paudyal; Mashhood Ali; Muhammad Khalid Tipu; Tofeeq Ur-Rehman
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-15       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.